Power 3 Medical Products 10Q 2008 Q2 Quarterly report

U.S. Securities and Exchange Commission

Washington, D.C. 20549

Form 10-Q

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2008

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ________________

COMMISSION FILE NO. 000-24921

Power3 Medical Products, Inc.

(Exact name of small business issuer as specified in its charter)

New York	0-24921	65-0565144
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

	3400 Research Forest Drive, Suite B2-3 Woodlands, Texas (Address of principal executive offices)	77381 (Zip Code)

Issuer’s Telephone Number: (281) 466-1600

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common stock, $.001 par value

(Title of class)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer., or a smaller reporting company.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act)? Yes ¨ No ý

The number of shares outstanding of the registrant’s common stock, par value $.001 per share, as of August 13, 2008, was 143,819,290 shares.

The number of shares outstanding of the registrant’s preferred Series B stock, par value $.001 per share, as of August 13, 2008, was 3,000,000 shares.

TABLE OF CONTENTS

PART I

ITEM 1.	Financial Statements	2

	Balance Sheets (unaudited)	2

	Statements of Operations (unaudited)	3

	Statement of Stockholders’ Deficit (unaudited)	4

	Statements of Cash Flows (unaudited)	6

	Notes to Financial Statements (unaudited)	8

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	24

ITEM 4.	Controls and Procedures	24

PART II

ITEM 1.	Legal Proceedings	26

ITEM 1A.	Risk Factors	27

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

ITEM 3.	Defaults Upon Senior Securities	27

ITEM 4.	Submission of Matters to a Vote of Security Holders	27

ITEM 5.	Other Information	27

ITEM 6.	Exhibits	27

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

BALANCE SHEETS

AS OF JUNE 30, 2008 AND DECEMBER 31, 2007

(unaudited)

	June 30, 2008			December 31, 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	97,970		$	125,679
Other Current Assets		23,780			23,247
TOTAL CURRENT ASSETS		121,750			148,926

OTHER ASSETS
Deferred Finance Costs, net of accumulated amortization of $304,149 and $176,952 at June 30, 2008 and December 31, 2007, respectively		15,000			127,197
Furniture, Fixtures and Equipment, net of accumulated depreciation of $100,106 and $98,960 at June 30, 2008 and December 31, 2007, respectively		7,450			5,799
Stock Held in Escrow		190,000			—
Deposits		5,450			21,598
TOTAL ASSETS	$	339,650		$	303,520

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts Payable	$	1,007,496		$	969,387
Notes Payable – in default		451,000			451,000
Notes Payable		140,000			50,000
Notes Payable to Related Parties		1,055,360			1,934,816
Convertible Debentures-in default, net of amortization of $1,194,733 and $1,178,865 at June 30, 2008 and December 31, 2007, respectively		642,542			645,190
Other Current Liabilities		674,921			1,242,936
Derivative Liabilities		1,573,445			3,794,305
TOTAL LIABILITIES		5,544,764			9,087,634

STOCKHOLDERS’ DEFICIT
Preferred Stock - $0.001 par value; 50,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding as of June 30, 2008 and December 31, 2007, respectively		3,000			—
Common Stock - $0.001 par value; 150,000,000 shares authorized; 143,019,290 and 108,352,636 shares issued and outstanding as of June 30, 2008 and December 31, 2007, respectively		143,020			108,353
Additional Paid-In Capital		63,533,121			60,191,104
Deficit Accumulated Before Entering Development Stage		(11,681,500	)		(11,681,500	)
Deficit Accumulated During Development Stage		(57,202,755	)		(57,402,071	)
TOTAL STOCKHOLDERS’ DEFICIT		(5,205,114	)		(8,784,114	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	339,650		$	303,520

The accompanying notes are an integral part of these financial statements.

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2008 AND 2007

and the period from May 18, 2004 (inception) through June 30, 2008

(unaudited)

	For the three month period ended June 30,						For the six month period ended June 30,						Period from May 18, 2004 Through June 30,
	2008			2007 (restated)			2008			2007 (restated)			2008 (restated)
REVENUE
Sales	$	-		$	-		$	-		$	121,724		$	426,224
Total revenue	$	-		$	-		$	-		$	121,724		$	426,224

OPERATING EXPENSES
Employee compensation and benefits		242,984			320,903			526,905			585,729			30,534,895
Professional and consulting fees		725,794			490,339			811,492			582,784			10,152,319
Impairment of goodwill		-			-			-			-			13,371,776
Impairment of intangible assets		-			-			-			-			179,788
Occupancy and equipment		23,444			48,638			67,940			71,181			600,344
Travel and entertainment		22,246			42,935			78,702			60,745			421,194
Write off lease		-			-			-			-			34,243
Other selling, general and administrative expenses		48,089			58,261			155,262			92,925			616,880
Total operating expenses	$	1,062,557		$	961,076		$	1,640,301		$	1,393,364		$	55,911,439

LOSS FROM OPERATIONS	$	(1,062,557	)	$	(961,076	)	$	(1,640,301	)	$	(1,271,640	)	$	(55,485,215	)

OTHER INCOME AND (EXPENSE)
Derivative gain (loss)	$	252,244		$	(644,485	)	$	2,420,860		$	(7,016,852	)	$	5,028,723
Gain on legal settlement		-			3,112			17,875			3,112			36,764
Loss on settlement of debt		(122,384	)		-			(122,384	)		-			(122,384	)
Interest income		(476	)		(1,020	)		575			-			7,866
Mandatory prepayment penalty		-			-			-			-			(420,000	)
Other expense		-			(398,317	)		-			(398,317	)		(196,176	)
Gain on issuance of stock		120,000			-			120,000			-			120,000
Gain on conversion of financial instruments		-			955,973			-			1,093,014			1,544,574
Interest expense		(196,621	)		(1,278,213	)		(585,237	)		(1,459,148	)		(4,999,203	)
Total other income (expense)		52,763			(1,362,950	)		1,851,689			(7,778,191	)		(1,000,164	)

NET INCOME (LOSS)	$	(1,009,794	)	$	(2,324,026	)	$	211,388		$	(9,049,831	)	$	(56,485,379	)
Deemed Dividend		-			-			(12,072	)		-			(29,707	)
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLERS	$	(1,009,794	)	$	(2,324,026	)	$	199,316		$	(9,049,831	)	$	(56,515,086	)
NET INCOME (LOSS) PER SHARE BASIC AND DILUTED	$	(0.01	)	$	(0.03	)	$	0.00		$	(0.12	)

Weighted average number of shares outstanding		128,055,498			82,967,919			121,821,879			78,068,603

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

STATEMENT OF STOCKHOLDERS' DEFICIT

FROM INCEPTION TO JUNE 30, 2008

	Common Stock						Preferred Stock						Additional Paid In			Deferred Compensation			Retained
	Shares			Par Value			Shares			Par Value			Capital			Expense			Earnings			Equity

Balances as of beginning of development stage May 18, 2004		14,407,630		$	14,407			3,870,000		$	3,870		$	14,225,974		$	—		$	(11,681,500	)	$	2,562,751
Issued shares for compensation		27,945,000			27,945			—			—			25,423,555			(25,451,500	)		—			—
Issued shares for services		4,910,000			4,910			—			—			4,850,090			(535,000	)		—			4,320,000
Issued shares for acquisition of equipment		15,000,000			15,000			—			—			13,485,000			—			—			13,500,000
Stock option expense		—			—			—			—			626,100			(626,100	)		—			—
Issued shares for cash		242,167			242			—			—			314,575			—			—			314,817
Cancelled shares per cancellation of agreement		(160,000	)		(160	)		—			—			(71,840	)		—			—			(72,000	)
Issued shares to convert Series A preferred shares to common shares		3,000,324			3,001			(3,870,000	)		(3,870	)		3,377,974			—			(3,380,975	)		(3,870	)
Stock based compensation		—			—			—			—			—			8,311,012			—			8,311,012
Net reclassification of derivative liabilities		—			—			—			—			(3,347,077	)		—			—			(3,347,077	)
Net loss (from May 18, 2004 to December 31, 2004)		—			—			—			—			—			—			(15,236,339	)		(15,236,339	)
Balances, December 31, 2004		65,345,121		$	65,345			—		$	—		$	58,884,351		$	(18,301,588	)	$	(30,298,814	)	$	10,349,294
Cancelled shares returned from employee		(1,120,000	)		(1,120	)		—			—			(1,307,855	)		—			—			(1,308,975	)
Issued shares for compensation		140,000			140			—			—			41,860			—			—			42,000
Issued shares for services		850,000			850			—			—			155,150			—			—			156,000
Amortize deferred compensation expense		—			—			—			—			—			13,222,517			—			13,222,517
Net loss		—			—			—			—			—			—			(27,134,865	)		(27,134,865	)
Balances, December 31, 2005		65,215,121		$	65,215			—		$	—		$	57,773,506		$	(5,079,071	)	$	(57,433,679	)	$	(4,674,029	)
Issued shares for services		2,449,990			2,449			—			—			311,865			—			—			314,314
Issued shares for cash		2,452,746			2,452			—			—			222,548			—			—			225,000
Issued shares for compensation		1,253,098			1,254			—			—			176,763			—			—			178,017
Adoption of FAS 123R		—			—			—			—			(475,324	)		475,324			—			—
Amortize deferred compensation expense		—			—			—			—			—			4,603,747			—			4,603,747
Net loss		—			—			—			—			—			—			(6,415,968	)		(6,415,968	)
Balances, December 31, 2006		71,370,955		$	71,370			—		$	—		$	58,009,358		$	—		$	(63,849,648	)	$	(5,768,920	)
Issued shares for services		1,810,000			1,810			—			—			282,390			—			—			284,200
Issued shares for conversion of debt		22,265,224			22,264			—			—			606,412			—			—			628,676
Issued shares for warrants exercised		5,270,832			5,272			—			—			336,396			—			—			341,668
Issued shares for cash		7,630,625			7,632			—			—			992,818			—			—			1,000,450
Placement agent fees		—			—			—			—			(58,500	)		—			—			(58,500	)
Stock received		—			—			—			—			100			—			—			100
Unreturned shares		5,000			5			—			—			4,495			—			—			4,500
Deemed dividend		—			—			—			—			17,635			—			(17,635	)		—
Net loss		—			—			—			—						—			(5,216,288	)		(5,216,288	)
Balances, December 31, 2007		108,352,636		$	108,353			—		$	—		$	60,191,104		$	—		$	(69,083,571	)	$	(8,784,114	)

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

STATEMENT OF STOCKHOLDERS' DEFICIT (CONTINUED)

FROM INCEPTION TO JUNE 30, 2008

	Common Stock				Preferred Stock				Additional Paid In		Deferred Compensation		Retained
	Shares		Par Value		Shares		Par Value		Capital		Expense		Earnings			Equity
Balances, December 31, 2007		108,352,636	$	108,353		3,870,000	$	—	$	60,191,104	$	—	$	(11,681,500	)	$	(8,784,114	)
Issued shares for services		9,082,910		9,083		—		—		757,258		—		—			766,341
Issued shares for cash		7,492,875		7,493		—		—		639,911		—		—			647,404
Issued shares for conversion of debt		16,932,536		16,933		— —		—		1,448,054		—		—			1,464,987
Issued shares for lawsuit settlement		325,000		325		— —		—		30,555		—		—			30,880
Issued shares for payables		833,333		833		—		—		97,167		—		—			98,000
Issued preferred shares		—		—		3,000,000		3,000		357,000		—		—			360,000
Deemed dividend		—		—		—		—		12,072		—		(12,072	)		—-
Net income		—		—		—		—		—		—		211,388			211,388
Balances, June 30, 2008		143,019,290	$	143,020		3,000,000	$	3,000	$	63,533,121	$	—	$	(68,884,255	)	$	(55,205,114	)

The accompanying notes are an integral part of these financial statements.

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2008 AND 2007

and the period from May 18, 2004 (inception) through June 30, 2008

(unaudited)

	June 30, 2008			June 30, 2007 (restated)			Period from May 18, 2004 through June 30, 2008
Operating Activities:
Net income (loss)	$	211,388		$	(9,049,831	)	$	(53,792,075	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
(Gain) loss on conversion of financial instruments		2,384			(1,093,014	)		(1,542,190	)
Impairment of goodwill		—			—			13,371,776
Impairment of intangible assets		—			—			179,788
Loss on previously capitalized lease		—			—			34,243
Amortization of debt discounts and deferred finance costs		444,549			1,299,375			2,971,291
Change in derivative liability, net of bifurcation		(2,420,860	)		7,016,852			(3,874,822	)
Stock based compensation		576,341			236,200			33,232,386
Stock issued for settlement of lawsuit		30,880			—			30,880
Depreciation expense		1,146			12,293			100,106
Other non cash items		—			—			(34,933	)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		616			(35,973	)		170,553
Accounts payable and other liabilities		146,241			558,745			2,761,049
Net cash used in operating activities		(1,007,315	)		(1,055,353	)		(6,391,948	)

Investing Activities:
Capital expenditures, net		(2,798	)		—			(141,800	)
Increase in other assets		—			—			(179,786	)
Net cash used in investing activities		(2,798	)		—			(321,586	)

Financing Activities:
Proceeds from borrowings under notes payable, net		290,000			875,000			3,318,430
Proceeds from sale of common stock		647,404			650,000			2,264,171
Principal payments on long term debt		—			(20,000	)		(32,478	)
Borrowing on debt related party		45,000			107,770			75,376
Principal payments on notes payable related party		—			(17,300	)		(17,300	)
Proceeds from CD, warrants and rights net of issuance cost		—			66,667			1,200,709
Net cash provided by financing activities		982,404			1,662,137			6,808,908

Net change in cash and cash equivalents		(27,709	)		606,784			95,374

Cash and cash equivalents, beginning of period		125,679			40,602			2,596
Cash and cash equivalents, end of period	$	97,970		$	647,386		$	97,970

The accompanying notes are an integral part of these financial statements.

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2008 AND 2007

and the period from May 18, 2004 (inception) through June 30, 2008

(unaudited)

	June 30, 2008		June 30, 2007 (restated)		Period from May 18, 2004 through June 30, 2008
Supplemental disclosures of cash flow information
Cash paid for:
Interest	$	—	$	—	$	59,840
Income taxes	$	—	$	—	$	—

Non-cash transactions
Restatement of notes payable to notes payable related parties	$	—	$	—	$	1,393,346
Exchange of convertible notes for stock	$	1,357,333	$	1,531,638	$	2,917,137
Stock issued for settlement of payables	$	83,270	$	—	$	89,967
Deemed dividend	$	12,072	$	—	$	29,707
Exchange of convertible preferred stock for common stock	$	—	$	—	$	3,380,975
Preferred stock issued for payables	$	360,000	$	—	$	360,000
Stock held in escrow	$	190,000	$	—	$	190,000

The accompanying notes are an integral part of these financial statements.

POWER3 MEDICAL PRODUCTS, INC.

(A Development Stage Enterprise)

NOTES TO FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION

The accompanying unaudited interim financial statements of Power3 Medical Products, Inc. (“Power3”or the “Company”) at June 30, 2008, have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in conformity with generally accepted accounting principles have been omitted or condensed pursuant to such rules and regulations. These statements should be read in conjunction with Power3’s Form 10-KSB for the year ended December 31, 2007. In management’s opinion, these interim financial statements reflect all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

Restatements

Restatements of previously reported financial results for the six month period ended June 30, 2007, were made. See Note 7.

Earnings Per Share

Basic and diluted earnings per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. The per share amounts include the dilutive effect of common stock equivalents in years with net income.

Earnings per share for the six month period ended June 30, 2008 is computed as follows:

	Net Income (Numerator)		Shares (Denominator)		Per-Share Amount
	$	211,388
Basic EPS
Income available to common stockholders	$	199,316		121,821,879	$	0.00
Effective Dilutive EPS *
Income available to common stockholders	$	199,316		128,560,062	$	0.00

*As of June 30, 2008, Power3 has 121,821,879 weighted average shares outstanding. The Company uses the treasury stock method to determine whether any outstanding options or warrants are to be included in the diluted earnings per share calculation. As of June 30, 2008, Power3 had 33,070,328 shares issuable on warrants exercisable as follows:

Exercise Price		Number Of Shares Issuable		Proceeds
$	0.04		2,125,000	$	85,000
	0.06		3,708,333		222,500
	0.08		12,845,829		1,027,666
	0.09		833,333		75,000
	0.10		13,557,833		1,355,783
			33,070,328	$	2,765,950

Using an average share price for the six month period ended June 30, 2008 of $0.105, the warrants result in a net additional possible dilution of 6,738,183 shares. This results in 128,560,062 shares used in the above calculation. An additional 4,586,266 warrants have been earned, but are not “in the money” and are therefore not included in this calculation, due to their anti-dilutive effect.

NOTE 2. GOING CONCERN

As shown in the accompanying financial statements, Power3 has an accumulated deficit of $68,884,255 as of June 30, 2008 and negative operating cash flows since inception of approximately $6,400,000. These conditions create an uncertainty as to Power3's ability to continue as a going concern.

Management is trying to raise additional capital through various funding arrangements. The financial statements do not include any adjustment that might be necessary if Power3 is unable to continue as a going concern.

NOTE 3. FINANCING ARRANGEMENTS

Securities Purchase Agreement—Convertible Debentures

The Company entered into a Securities Purchase Agreement, dated October 28, 2004 (the “Agreement”) with certain accredited investors (the “Purchasers”). Pursuant to the Agreement, the Purchasers agreed to purchase convertible debentures due three (3) years from the date of issuance in the aggregate principal amount of $3,000,000. The Agreement also provides warrants to purchase shares of the Company's common stock and additional investment rights to purchase additional convertible debentures. In connection with the Agreement, the Company also entered into a Registration Rights Agreement with the Purchasers that requires the Company to (i) file a registration statement with the SEC registering the resale of the shares of common stock issuable upon conversion of the debentures and the exercise of the warrants, (ii) achieve effectiveness within a stated period and (iii) maintain effectiveness of the registration statement. Failure to meet these requirements will require the Company to incur liquidating damages amounting to 2.0% for each month.

On October 28, 2004, the Company issued the Purchasers the first $1,000,000 in aggregate principal amount of such debentures at the initial closing under the Agreement. Effective January 26, 2005, the Company issued and sold, to a sub-group of the original investors, a second tranche of $400,000 aggregate principal amount of debentures. Subject to the conditions set forth in the Agreement, all purchasers are required to purchase the remaining $1,600,000 in aggregate principal amount of such debentures at the final closing, which is to occur on or before the fifth trading day after the effective date of the registration statement. The Company is currently in default under the Agreement and the previously issued debentures and related registration rights agreement, and therefore the conditions of the Agreement will not be satisfied or otherwise met on a timely basis. Consequently, there are no assurances that the Purchasers will purchase all or any portion of the remaining $1,600,000 aggregate principal amount of debentures. The $1,400,000 aggregate principal amount of debentures that were issued October 28, 2004 and January 26, 2005 are due and payable in accordance with their original terms in full three years after the date of issuance and bear interest at a default rate of 18%. The debentures are convertible into shares of common stock at the following conversion price, which varies relative to the Company’s trading stock price, as follows: $0.90 per share, provided however if the lesser of (i) 75% of the average of the 5 consecutive Closing Prices immediately prior to the Effective Date, as defined in the Securities Purchase Agreement, and (ii) the Closing Price on the Effective Date (the lesser of (i) and (ii) being referred to as the “Effective Date Price”) is less than the Conversion Price, the Conversion Price shall be reduced to equal the Effective Date Price.

Under the Agreements, the Purchasers also received warrants to purchase an aggregate of up to 2,500,000 and 333,333 shares of common stock for tranche one and two, respectively, and additional investment rights to purchase up to an additional $2,500,000 of convertible debentures. The warrants are exercisable at a price of $0.08 per share, subject to adjustment, including anti-dilution protection. The additional investment rights are exercisable at a price equal to the principal amount of the debentures to be purchased, for (1) a period of nine months following the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement, or (2) a period of 18 months from the date of issuance of the additional investment rights, whichever is shorter. The rights debentures will have the same terms as the debentures described above, except that the conversion price will be equal to $1.08.

The Company is in default under the provisions of the Agreement, Registration Rights Agreement and previously issued debentures. The aggregate amount payable upon an acceleration by reason of an event of default is equal to the greater of 130% of the principal amount of the debentures to be prepaid or the principal amount of the debentures to be prepaid, divided by the conversion price on the date specified in the debenture, multiplied by the closing price on the date set forth in the debenture. The default stems from the Company’s inability to obtain effectiveness of the registration statement on Form SB-2, as amended (File No. 333-122227) filed pursuant to the registration rights agreement. The registration statement was withdrawn on June 20, 2007. As of the six months ended June 30, 2008, the Company has settled with a number of its convertible debenture holders and expects to settle with the remaining convertible debenture holders in 2008.

Of the $1,400,000 Convertible Debentures mentioned above the Company has settled $884,990 as of the six months ended June 30, 2008 and the year ended December 31, 2007, resulting in a balance of $515,010 at June 30, 2008.

On April 3, 2007, the Company entered into a joint venture agreement with NeoGenomics to form a Contract Research Organization (CRO) and collaborate on research work in the future. Currently, Power3 and NeoGenomics are in discussion to revise the expired Letter of Intent between the respective organizations.

On June 30, 2008, the Company issued a $200,000 15% convertible debenture with detachable warrants to purchase 3,500,000 shares of common stock to Able Income Fund LLC. The note has a maturity date of September 15, 2009. The warrants have a five-year term and a strike price of $0.06.

Power3 has converted several notes and plans to continue doing so. In some instances, Power3 has offered terms of conversion lower than the original agreement including raising the strike price of warrants attached to these instruments. As a result of this additional consideration, upon conversion the Company recorded a $122,384 loss on the conversion of notes during the six months ended June 30, 2008. The change in the conversion terms represented greater than 10% of the principal value of the notes and as a result extinguishment accounting has been applied consistent with EITF 96-19.

As a result of the convertible debentures, Power3 has determined that the conversion feature of the convertible debentures and the warrants issued with the convertible debentures are embedded derivative instruments pursuant to Statement of Financial Accounting Standards (SFAS) 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended. Under the provisions of EITF Issue No. 00−19, “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock,” the accounting treatment of these derivative financial instruments requires that the Company record the derivatives at their fair values as of the inception date of the note agreements and at fair value as of each subsequent balance sheet date as a liability. Any change in fair value is recorded as non-operating, non-cash income or expense at each balance sheet date. The Company estimates fair value of warrants using the Black−Scholes option pricing model and the conversion feature of their notes using the binomial lattice model. The estimates inherent within these models directly affect the reported amounts of the derivative instrument liabilities.

Deemed Dividend

As part of Power3’s attempt to induce warrant holders to exercise its warrants, the strike price of certain warrants was reduced resulting in a deemed dividend of $12,072, consistent with EITF 98-5. The deemed dividend was valued using the Black-Scholes model immediately before and after the inducement consistent with paragraph 51 of SFAS 123R.

Convertible Debentures, Warrants and Additional Investment Rights:

The carrying values of the Company’s convertible debentures amounted to $642,542 and $645,190, at June 30, 2008 and December 31, 2007, as follows.

	As of			As of
	June 30,			December 31,
	2008			2007
Convertible Debentures:
Securities Purchase Agreement Holders	$	515,010		$	515,010
Discount		—			(86,844	)

Note 3:
Chosid		—			200,000
Wood		—			120,000
Seyburn		100,000			100,000
Discount on Note 3		—			(210,417	)

Note 4:
NeoGenomics		200,000			200,000
Discount on Note 4		(172,468	)		(192,559	)

Note 5:
Able Income Fund		200,000			—
Discount on Note 5		(200,000	)		—
Totals	$	642,542		$	645,190

The following tabular presentation reflects the components of derivative financial instruments on the Company’s balance sheet at June 30, 2008 and December 31, 2007:

Derivative Liabilities:	June 30, 2008		December 31, 2007
Common stock warrants	$	526,146	$	1,563,183
Embedded conversion feature		737,022		1,205,719
Additional investment rights		214,588		642,792
Other derivative instruments		95,709		382,611
	$	1,573,445	$	3,794,305

The fair values of certain other derivative financial instruments (warrants) that existed at the time of the initial Debenture Financing were re-classed from stockholders’ equity to liabilities when, in connection with the Debenture Financing, the Company no longer controlled its ability to share-settle these instruments.

Other Notes, Preferred Stock and Warrants:

During November and December 2005, the Company issued $300,000 (2 tranches of $150,000) face value, 11% notes and detachable warrants to purchase 2,000,000 shares of common stock to Trinity Financing Investments Corporation. The warrants have eight-year terms and strike prices of $0.25 for 1,000,000 shares and $0.14 for 1,000,000 shares. The note was paid in full as of the year ended December 31, 2007.

Other derivative financial instruments consist of various warrants that were issued prior to and subsequent to the debenture financing and were reclassified from stockholders’ equity or initially accounted for as liabilities, at fair values, since share-settlement was not within the Company’s control after the debenture financing.

Notes Payable, in Default and to Related Parties

The total Notes Payable to related parties decreased from $1,934,816 as of the year ended December 31, 2007, to $1,055,360 as of the period ended June 30, 2008 as follows:

	As of June 30, 2008		As of December 31, 2007
Notes payable in default:
Cordillera I	$	251,000	$	251,000
Cordillera II	$	200,000	$	200,000
Totals	$	451,000	$	451,000
Notes payable:
Kazanowski	$	50,000	$	50,000
Kronshage	$	55,000	$	—
Heller	$	35,000	$	—
	$	140,000	$	50,000
Notes payable - related parties:
Rash	$	45,000	$	924,456
Goldknopf	$	975,360	$	975,360
Rosinski	$	35,000	$	35,000

Totals	$	1,055,360	$	1,934,816

NOTE 4. OTHER SIGNIFICANT EQUITY TRANSACTIONS

Deemed distribution:

During the 2^nd Quarter of 2004, the Company issued 15,000,000 shares of common stock as consideration for a set of assets and liabilities purchased from Advanced BioChem in the asset purchase transaction of May 18, 2004. Because this transaction was between individuals and entities considered to be related parties, under the rules of the SEC, the assets are recorded at historical cost and the amount in excess of historical cost is considered to be a deemed distribution to the shareholders. As part of that transaction, the Company recorded a deemed distribution of $ 13,371,776 as the difference between the market value of the stock at $0.90 per share on the date of the agreement ($13,500,000) and $128,224, debt in excess of the assets received in the transaction.

During the 4^th Quarter of 2004, the Company converted Series A Preferred Stock owned by former management of the Company to common shares, per the terms of the Series A Preferred Stock held by these individuals (Novak, Gray and Leonard). As part of that transaction the Company recorded a deemed distribution of $3,380,975, the market value of the common shares issued at the date of issue of the common shares. Since both of these deemed distributions occurred after May 18, 2004, the date the Company entered the development stage, the total of these two deemed distributions ($16,752,751) is included in the deficit accumulated during the development stage in the balance sheet of the Company.

Deemed dividend:

As part of Power3’s attempt to induce exercise, the strike price of several warrants was reduced resulting in a deemed dividend of $12,072 and $17,635, consistent with EITF 98-5, for the six months ended June 30, 2008 and the year ended December 31, 2007, respectively. The deemed dividends were valued using the Black−Scholes model immediately before and after the inducement consistent with paragraph 51 of SFAS 123R.

Preferred shares issued during the six-month period ended June 30, 2008:

3,000,000 shares of preferred Series B stock were issued to officers of the Company pursuant to employment agreements. The shares were valued at $360,000 based upon the closing price of our common stock at the grant date resulting in a gain on extinguishment of debt of $120,000.

Shares issued for cash during the six-month period ended June 30, 2008:

7,492,875 shares of common stock were issued for cash to private investors in the amount of $647,404.

Shares issued for payables during the six-month period ended June 30, 2008:

833,333 shares of common stock were issued in payment on outstanding invoices for services. The shares were valued at $98,000 based upon the closing price of our common stock at the grant date resulting in a loss on extinguishment of debt of $14,730.

Shares issued for services during the six-month period ended June 30, 2008:

9,082,910 shares of common stock were issued for services to employees and consultants. The shares were valued at $766,341 based upon the closing price of our common stock at the grant date. 2,000,000 of these shares are being held in escrow.

Shares issued in settlement of legal proceedings during the six-month period ended June 30, 2008:

325,000 shares of common stock were issued in settlement of a dispute with a former employee as mentioned above. The shares were valued at $30,880 based upon the closing price of our common stock at the grant date.

Shares issued for conversion of debt during the six-month period ended June 30, 2008:

16,932,536 shares of common stock were issued for conversion of convertible notes in the amount of $1,357,333 as discussed in Note 3 above resulting in a loss on extinguishment of debt of $107,654.

NOTE 5. COMMITMENTS AND CONTINGENCES

On October 28, 2005, Power3 received notice of a Petition to Enforce Foreign Judgment citation filed against the Company by KForce regarding an employment fee adjudicated in December 2003 in the state of Florida against the Company, in the amount of $15,873, together with $4,735 in interest. Power3 does not agree with the Foreign Judgment and is attempting to resolve the issue prior to enforcement. No resolution has been achieved on this issue at this time; however the Company is endeavoring to resolve the petition. This debt is not recorded in accounts payable by the Company because it is the Company’s position that the judgment should never have been entered against Power3, but rather against a different corporate entity, not related to Power3 in any way, at this time. The Company’s attorney in this matter feels that no loss is probable, nor will the Company be obligated to pay any sums whatsoever on this matter. The Company has pled improper party and expects to be vacated from the suit since it does not apply to the Company. Power3 has counterclaimed KForce for frivolous claims.

On March 12, 2008, all matters involving the dispute over the taking, by an ex-employee, of certain trade secrets, defamation and wrongful interference with Power3's contractual relations with other parties, and a pendent wage claim for severance pay, were resolved. In settlement the Company has paid the ex-employee $35,000 and has issued to the ex-employee 325,000 shares of the Company’s common stock with restrictions.

In October of 2006, Trinity Financing filed a lawsuit against the Company claiming default on a promissory note dated December 9, 2005. As security for the Note, Steven Rash and Ira Goldknopf pledged their personal restricted shares of the Company's stock. As a result of the alleged default in payment of the Note, Trinity Financing seeks to have the restrictive legend removed so the shares may be sold by Trinity Financing in satisfaction of the loan. The Company denied the material allegations and asserted three counterclaims against Trinity Financing. The company asserted that the Note, as well as a prior promissory note executed in favor of Trinity Financing, are usurious. The matter was settled February 4, 2008 with the removal of the restrictive legend.

On August 13, 2007, Gryphon Master Fund, LP and GSFF Master Fund, LP filed a lawsuit against the Company claiming a breach of a Securities Purchase Agreement, Convertible Debentures, and Registration Rights Agreement. The plaintiffs claimed the Company failed to timely obtain an effective registration statement for the shares issued to the plaintiffs and refused to recognize anti-dilution rights of the plaintiffs. The Company denies the material allegations of the complaint and asserts numerous affirmative defenses. Power3 entered into settlement negotiations as of April 20, 2008. On August 13, 2008 the claim above, note, warrants, and all applicable penalties were settled in exchange for 5,240,000 shares of common stock valued at approximately $420,000 based upon the closing price of our common stock at the settlement date.

NOTE 6. SUBSEQUENT EVENTS

On July 18, 2008 the Company entered into a private offering with Golden Gate Investors, Inc. for an aggregate of up to $1,000,000 of 6% convertible debentures.

On July 28, 2008 the Company issued 800,000 shares of common stock in payment of legal services. The shares were valued at $68,000 based upon the closing price of our common stock at the grant date.

On July 29, 2008 the Company issued a $250,000, 15% convertible debenture with detachable warrants to purchase 4,500,000 shares of common stock to Able Income Fund LLC. The note has a maturity date of October 15, 2009. The warrants have a five-year term and a strike price of $0.06.

On August 13, 2008 our lawsuit with Gryphon Master Fund was settled and as a result the related note, warrants, and all applicable penalties were settled in exchange for 5,240,000 shares of common stock valued at approximately $420,000 based upon the closing price of our common stock at the settlement date.

NOTE 7. RESTATEMENT

The Company has identified certain accounting errors related to derivative liabilities which resulted in changes to derivative loss, interest expense and loss on conversion of financial instruments among other errors.

The effect on the statement of operations for the six months ended June 30, 2007 as a result of the adjustments was an increase in net loss of $2,161,894 and a $0.03 increase in net loss per share.

The effect on the balance sheet was an increase of $2,971,435 in total liabilities.

In all other material respects, the financial statements are unchanged.

Following is a summary of the unaudited restatement adjustments:

As of June 30, 2007

SUMMARY BALANCE SHEET

(unaudited)

	As Reported (unaudited)			Adjustment			As Restated (unaudited)
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	647,387		$	—		$	647,387
Other Current Assets		900			—			900
TOTAL CURRENT ASSETS		648,287						648,287

OTHER ASSETS
Deferred Finance Costs, net of amortization		113,569			92,256			205,825
Intellectual Property		179,786			—			179,786
Furniture, Fixtures and Equipment, net of accumulated depreciation		4,082			—			4,082
Deposits		41,073			—			41,073
TOTAL ASSETS	$	986,797		$	92,256		$	1,079,053

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts Payable	$	983,725		$	—		$	983,725
Notes Payable – in default		511,822			—			511,822
Notes Payable to Related Parties		1,754,440			30,376	) (a)		1,784,816
Convertible Debentures-in default, net of amortization		1,053,455			(623,164	) (b)		430,291
Other Current Liabilities		1,653,880			(214,301	) (c)		1,439,579
Derivative Liabilities		5,577,455			3,778,524	(b)		9,355,979
TOTAL LIABILITIES		11,534,777			2,971,435			14,506,212

STOCKHOLDERS’ DEFICIT
Preferred Stock		—			—			—
Common Stock		94,181			5	(d)		94,186
Additional Paid-In Capital		60,095,424			(717,290	) (d)		59,378,134
Deficit Accumulated Before Entering Development Stage		(11,681,500	)		—			(11,681,500	)
Deficit Accumulated During Development Stage		(59,056,085	)		(2,161,894	) (e)		(61,217,979	)
TOTAL STOCKHOLDERS’ DEFICIT		(10,547,980	)		(2,879,179	)		(13,427,159	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	986,797		$	92,256		$	1,079,053

(a)	To adjust notes payable to actual based upon previous errors.
(b)	To adjust to correct accounts associated with derivatives.
(c)	To adjust to correct accounts associated with derivative and to correct accrued interest.
(d)	To adjust to correct stock for conversion.
(e)	To adjust accumulated deficit largely due to errors associated with derivatives.

For the three months ended June 30, 2007

SUMMARY STATEMENT OF OPERATIONS

(unaudited)

	Three Months Ended June 30, 2007						Three Months Ended June 30, 2007
	As Reported (unaudited)			Adjustments (unaudited)			As Restated (unaudited)
REVENUE
Sales	$	—		$	—		$	—
Total Revenue		—			—			—
OPERATING EXPENSES
Employee compensation and benefits		135,350			185,553	(a)		320,903
Professional and consulting fees		177,339			313,000	(b)		490,339
Occupancy and equipment		41,410			7,228	(c)		48,638
Travel and entertainment		42,935			—			42,935
Other selling, general and administrative expenses		40,651			17,610	(a)		58,261
Total operating expenses		437,685			523,391			961,076

LOSS FROM OPERATIONS		(437,685	)		(523,391	)		(961,076	)

OTHER INCOME AND (EXPENSE)
Derivative gain (loss)		(321,666	)		(322,819	) (e)		(644,485	)
Gain on legal settlement		—			3,112	(a)		3,112
Interest income		2,092			(3,112	) (a)		(1,020	)
Other expense		—			(398,317	) (a)		(398,317	)
Gain on conversion of financial instruments					955,973	(a)		955,973
Interest expense		(511,567	)		(766,646	) (d)		(1,278,213	)
Total other income (expense)		(831,141	)		(531,809	)		(1,362,950	)

NET LOSS	$	(1,268,826	)	$	(1,055,200	)	$	(2,324,026	)

NET LOSS PER SHARE BASIC AND DILUTED	$	(0.02	)	$	(0.01	)	$	(0.03	)

Weighted average number of shares outstanding		83,793,113			(825,194	)		82,967,919

(a)	To adjust to correct account to actual based on previous errors.
(b)	To adjust to correct account associated with stock for services.
(c)	To correct account balance due to error in not accruing rent.
(d)	To adjust to correct accounts associated with derivatives.

For the six months ended June 30, 2007

SUMMARY STATEMENT OF OPERATIONS

(unaudited)

	Six Months Ended June 30, 2007						Six Months Ended June 30, 2007
	As Reported (unaudited)			Adjustments (unaudited)			As Restated (unaudited)
REVENUE
Sales	$	121,724		$	—		$	121,724
Total revenue		121,724			—			121,724

OPERATING EXPENSES
Employee compensation and benefits		586,563			(834	) (a)		585,729
Professional and consulting fees		381,784			201,000	(b)		582,784
Occupancy and equipment		74,382			(3,201	) (c)		71,181
Travel and entertainment		60,745			—			60,745
Other selling, general and administrative expenses		89,723			3,202	(a)		92,925
Total operating expenses		1,193,197			200,167			1,393,364

LOSS FROM OPERATIONS		(1,071,473	)		(200,167	)		(1,271,640	)

OTHER INCOME AND (EXPENSE)
Derivative gain (loss)		(3,809,107	)		(3,207,745	) (d)		(7,016,852	)
Interest income		3,112			—			3,112
Other expense		(531,062	)		132,745	(a)		(398,317	)
Loss on conversion of financial instruments		(397,871	)		1,490,885	(a)		1,093,014
Interest expense		(1,081,536	)		(377,612	) (d)		(1,459,148	)
Total other income (expense)		(5,816,464	)		(1,961,727	)		(7,778,191	)

NET LOSS	$	(6,887,937	)	$	(2,161,894	)	$	(9,049,831	)

NET LOSS PER SHARE BASIC AND DILUTED	$	(0.09	)	$	(0.03	)	$	(0.12	)

Weighted average number of shares outstanding		78,523,532			(454,929	)		78,068,603

(a)	To adjust to correct account to actual based on previous errors.
(b)	To adjust to correct account to actual based on previous errors.
(c)	To correct account balance due to error in not accruing rent.
(d)	To adjust to correct accounts associated with derivatives.

Item 2. Management’s Discussion and Analysis

Power3 Medical Products, Inc. (the “Company” or “Power3”) was incorporated in the State of Florida on May 15, 1992 and merged into a New York Corporation in 1994, under the name of Sheffield Acres, Inc. Power3 and its wholly owned subsidiaries, C5 Health, Inc. (“C5”), which was officially dissolved in the State of Delaware and in the State of Florida effective December 31, 2003 and Power3 Medical, Inc., a Nevada Corporation, were engaged in sales, distribution and services for the healthcare industry. On September 12, 2003 Surgical Safety Products, Inc. amended its Certificate of Incorporation to (a) declare a 1:50 reverse split of its common stock; (b) increase its authorized capital to 150,000,000 shares of common stock and 50,000,000 shares of preferred stock; and (c) change its name to Power3 Medical Products, Inc.

The Company transitioned to the development stage, from previously being an operating company, as of the Company’s asset purchase transaction with Advanced BioChem on May 18, 2004. As a development stage company, Power3 is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, ALS, Alzheimer’s disease and Parkinson’s disease.

Series B Preferred Stock

Pursuant to two employment agreements with two officers, the Company agreed to issue to such officers an aggregate of 3,000,000 shares of Series B Preferred Stock. On September 6, 2007, the Company filed the Certificate of Amendment necessary to designate the Series B Preferred Stock and the powers, designations and relative rights of the Series B Preferred Stock. 3,000,000 shares of Series B Preferred Stock were issued to the two officers on April 23, 2008.

SCIENTIFIC DEVELOPMENTS

CLIA Certification

On March 25, 2008, Power3 received its CLIA (Clinical Laboratory Improvement Amendment) compliance recertification following a CLIA regulatory inspection. Power3 earned its CLIA recertification to offer high complexity tests after meeting standards for knowledge, training, expertise, quality control, quality assurance, and testing proficiency. With CLIA recertification, Power3 is able to continue offering its blood serum based tests, BC-SeraPro^™ and NuroPro^®. Receipt of Power3’s CLIA recertification of compliance is a major milestone. This achievement reflects Power3’s desire to offer the highest quality proteomic tests in its continuing mission to commercialize the company’s proteomic discoveries and serve the medical and scientific communities.

Power3’s scientific team is currently headed by its CLIA Laboratory Director and Director of Biochemistry, Dr. Essam A. Sheta and its Director of Proteomics, Dr. Ira L. Goldknopf. Drs. Sheta and Goldknopf are pioneers in the science of proteomics, protein biochemistry and cancer cell signaling and have made significant biochemical and proteomic discoveries. The scientific team at Power3 has leveraged these significant insights and has made progress in the discovery of unique disease protein footprints by the use of biomarkers in breast cancer, neurodegenerative diseases, and drug resistance to chemotherapeutic agents.

PRODUCT CANDIDATES

Power3 plans to target the protein-based diagnostic and drug targeting markets utilizing the Company’s portfolio of proprietary disease biomarkers. In the area of neurodegenerative diseases and breast cancer, the Company has completed research and clinical validation studies involving over 2,000 patient samples and is utilizing biostatistical analysis to monitor panels of biomarkers for diagnostic sensitivity, specificity, positive predictive value, and negative predictive value. By testing patient body fluids and tissues, such as serum, nipple aspirate fluid, and bone marrow aspirate, the Company has discovered unique snapshots of protein patterns in over 2,000 patient samples that cover a broad range of diseases including:

o	Cancers such as breast, leukemia, bladder, stomach, and esophageal; and

o	Neurodegenerative diseases such as Alzheimer’s, ALS, and Parkinson’s disease.

The Company’s discovery platform uses proprietary methodologies, trade secrets, and accepted proteomic technologies that have been optimized and validated for reproducible discovery and analysis of disease specific biomarkers in clinical patient samples. Following sample preparation, a 2D Gel Electrophoresis system is used for the separation of proteins. The gels are stained, digitally scanned and the digital images are analyzed with unprecedented reproducibility and sensitivity for quantitative differences of protein biomarkers in disease vs. control patient samples. These differences are evaluated using advanced biostatistical analysis to generate statistical models for the disease and control sample groups. This statistical model is then applied to new patient samples and used to predict their diagnosis. Biomarkers of interest can be removed from the 2D gel matrix and analyzed by fingerprinting on a liquid chromatograph - tandem mass spectrometer. This information is then cross-referenced on a worldwide database to identify the protein of origin. This process requires a great deal of proteomics experience and expertise to make an accurate identification. In addition, all of the procedures used in Power3’s diagnostic tests are scalable. The Company’s proteomics platform delivers significant discoveries exhibiting validated, reproducible, and reliable biomarkers over a broad quantitative range and linearity for use in diagnostic proteomic assays.

The Company has successfully identified more than 543 protein biomarkers that are differentially expressed in response to disease by employing its proprietary technologies gained from over 60 years of combined experience in protein biochemistry.

Power3 has transitioned from a company focused on research and development to one that is demonstrating “proof of concept” of its technology, as it enters the commercialization stage for its technology, products and services. The Company is engaged in the process of developing a portfolio of products including BC-SeraPro^™, a proteomic blood serum test for the early detection of breast cancer, and NuroPro^®, a proteomic blood serum test for the detection of neurodegenerative diseases including Alzheimer’s, Parkinson’s and ALS diseases.

DEVELOPMENT OF BC-SeraPro^™, A PROTEOMIC BREAST CANCER SCREENING TEST

Breast cancer is the second leading cause of cancer deaths in women and results in 40,000 deaths annually, with over $7 billion spent on breast cancer diagnosis annually. An important factor in surviving cancer is early detection and treatment. According to the American Cancer Society Surveillance Research, when breast cancer is confined to the breast, the five-year survival rate for early stages is close to 100%. Due to the limitations of the current diagnostic techniques of mammograms and self-examination, the presence of breast cancer is often missed or tests are inconclusive. The limitations and lack of accuracy of the current diagnostic tests highlight the need for a test that can detect the presence of breast cancer much earlier and more accurately.

BC-SeraPro^™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The concentration of the biomarkers from a patient’s serum sample is compared to Power3 Medical Products’ extensive patient database. Statistical analysis by linear discriminant function will analyze the patient’s biomarker concentrations and assign a probability score for the diagnosis of the patient sample. The probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro^™ test should not be considered a stand alone diagnosis nor a guarantee, but are intended to be used in conjunction with other breast cancer diagnostic tools.

This test was developed and its performance characteristics determined by the Power3 Medical Products laboratories. It has not been approved by the U.S. Food and Drug Administration. The FDA has determined that such approval is not necessary. This test is performed solely at the Power3 Medical Products’ laboratory and is used for clinical purposes. It should not be regarded as investigational or for research. Power3’s laboratory has been certified under the Clinical Laboratory Improvement Amendment of 1988 (“CLIA”) as qualified to perform high complexity clinical testing.

Because early stage breast cancer is asymptomatic, the only way to detect it is through screening. Mammography is currently the widely accepted method for breast cancer screening. However, most women who have an abnormal mammogram do not have cancer.

Mammography often leads to identification of a “probably benign” lesion or an inconclusive mammogram. Clinicians may be reluctant to refer such a patient for a biopsy; they may also be reluctant to do nothing. Often such patients are referred for frequent repeat mammography examinations.

The availability of an accurate and minimally-invasive test would avoid such repeated mammogram exams, with their attendant discomfort, inconvenience, x-ray exposure, and emotional stress. In such cases, BC-SeraPro^™, which in a 60 patient blinded study, demonstrated an 80% sensitivity and 87% specificity for the detection of breast cancer, could exclude malignancy at higher accuracy than mammography. As well, BC-SeraPro^™ is unlikely to not identify cancer in those women who have it.

BC-SeraPro^™ is an ideal diagnostic test to evaluate breast cancer abnormalities found by mammogram or breast examination. The test would distinguish women who should have a biopsy from those who can safely avoid one. BC-SeraPro^™ could detect the disease at a point when treatment is both more effective and less expensive.

During the quarter ending June 30, 2008, Power3 continued its blood serum breast cancer biomarker discovery program using blood serum samples collected from clinical validation sites, in collaboration with Dr. Alan Hollingsworth at the Mercy Woman’s Center in Oklahoma City, OK and Dr. Leroy Leeds at Obstetrics & Gynecological Associates, PA in Houston, TX. The Company believes that there are many advantages to a simple blood test over other types of breast cancer diagnostics, such as mammography, not the least of which is the ready acceptance by patients to having blood drawn. To date, in the latest clinical research/validation study involving Mercy Woman’s Center and Obstetrics & Gynecological Associates, 97 patient samples have been received and analyzed. The results continue to meet the Company’s expectations.

During the quarter, discussions were initiated to commence BC-SeraPro™ clinical validation studies in several Middle Eastern countries and in Greece. To commercialize BC-SeraPro™ in the Middle Eastern countries, Power3, in collaboration with the Princess Haya Biotechnology Center in Irbid, Jordan, hosted Mr. Yazan Akkam for two weeks of laboratory training in Power3’s propietory sample processing and analysis by 2D gel electrophoresis. Mr Akkam’s training will help Power3 accelerate the process of sample analysis for future commercialization of the test in Jordan. Dr. Said Jaradat, the Director of Princess Haya Biotechnology Center, has acknowledged this collaboration and shared the Center’s collaboration experience with Power3 in his talk with the President of the National Institute of Health (NIH) during his visit to Jordan. Power3 plans to commercialize BC-SeraPro™ in Jordan as soon as the Company finishes the validation study with the Princess Haya Biotechnology Center. This clinical validation study is expected to be concluded by the end of the third quarter, 2008.

Power3 is finalizing the research and development program for BC-SeraPro^™ and is moving forward with a strategy of providing a breast cancer diagnostic test that is utilitarian, accurate, and inexpensive. A patient's protein biomarker profile can now be employed to detect abnormal and pathological states, as reflected in the serum proteome. Application of this test will have a future impact on how breast disease will be diagnosed, monitored, and managed and is intended to be used in conjunction with mammography, breast MRI and other diagnostic tools used in the detection of breast cancer.

How BC-SeraPro^™ Works

BC-SeraPro^™ is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will be subjected to protein separation by 2D gel electrophoresis followed by analysis of the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The biomarkers in the panel have been selected for their ability to discriminate breast cancer patients from non-cancerous patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and assigns a probability score. The probability score indicates to the physician that the patient “has cancer” or is “cancer-free.” The score reflects how strongly the patient sample fits the biostatistical model and if the patient should be recommended for further follow-up by the clinician.

Blood serum collection is a routine procedure performed by a clinician. A small sample of blood is drawn from a vein. When a blood sample is collected and stored in a tube without anticoagulant, it forms a clot after 30-60 minutes. The liquid portion remaining is the blood serum. This serum sample is then frozen and transported to the Power3 Medical CLIA certified laboratory, utilizing pre-approved carriers/delivery services, where sample preparation and analysis begins.

DEVELOPMENT OF NuroPro^®, A PROTEOMIC NEURODEGENERATIVE DIAGNOSTIC SCREENING TEST

Early detection of neurodegenerative disease generally results in better patient outcomes. Three neurodegenerative diseases of particular interest are Alzheimer’s disease, Parkinson’s disease and ALS (Amyotrophic Lateral Sclerosis). The Alzheimer’s Association reports that Alzheimer’s disease is the most common form of dementia, affecting over 5.1 million Americans, of which 4.9 million are 65 or older. Every 72 seconds, someone in America develops Alzheimer’s disease and by mid-century someone will develop Alzheimer’s every 33 seconds. People as young as 30 years old can contract the disease and one in ten people age 65 and over have Alzheimer’s disease. In addition, the American Parkinson’s Disease Association reports that more than 1.5 million people in the U.S. have Parkinson’s disease, affecting about 1 in 100 Americans over the age of 60, and a new case of Parkinson’s disease is diagnosed every 9 minutes. On a smaller scale, the ALS Association reports that an average of approximately 30,000 Americans are afflicted with ALS, with 5,000 new cases diagnosed annually.

Currently, Power3 is using a panel of 59 protein biomarkers employed in the development of the NuroPro^® blood serum-based tests for four disease diagnostics including neurological diseases of motor control such as Parkinson’s disease, ALS and similarly presenting like disorders; ALS specific tests for ALS vs. ALS-like disorders; Alzheimer’s disease specific tests; and a Parkinson’s disease specific test. Pre-IDE applications for the first two diagnostic tests have been filed with the U.S. Food and Drug Administration (FDA). With the NuroPro® test, which involves monitoring the concentration of 59 differentially expressed blood serum proteins, the Company has identified groups of unique markers that appear to distinguish normal patients from those with motor neuron, cognitive, and other neurological disorders. These biomarkers were selected from the analysis of over 850 blood serum patient samples.

How NuroPro^®Works

The NuroPro^® test has the potential to become the first clinical diagnostic test available for the detection of neurodegenerative diseases.

NuroPro^® is a series of three separate and distinct blood serum tests designed to diagnose Alzheimer’s, Parkinson’s or Lou Gehrig’s disease (ALS) in individuals. The test is based on proteomic technology, in which a blood serum sample is drawn from a patient, and monitors the concentration of selected biomarkers residing in a panel of blood serum protein biomarkers that determines if a patient has a neurodegenerative disease, such as Alzheimer’s, Parkinson’s or Lou Gehrig’s disease (ALS). The biomarkers in the panel have been selected for their ability to discriminate diseased from non-diseased patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and assigns a probability score. The probability score indicates to the physician that the patient has a neurological disease or is disease-free. The score reflects how strongly the patient sample fits the biostatistical model and if the patient should be recommended for further follow-up by the clinician.

NEURODEGENERATIVE RESEARCH/CLINICAL VALIDATION STUDIES

University of Thessaly School of Medicine / Dr. Katerina Markopoulou

On November 11, 2006, University of Thessaly School of Medicine in Larissa, Greece signed a research agreement with Power3 focusing on the proteomic discovery of biomarkers for Parkinson’s disease. The collaboration will also extend to cover other neurodegenerative diseases including Alzheimer’s disease and ALS (Amyotrophic Lateral Sclerosis - Lou Gehrig's disease). According to the agreement, The University of Thessaly will provide Power3 with clinically confirmed samples of neurodegenerative disease, including age and gender matched control samples. The Principal Investigator is Katerina Markopoulou, MD PhD with the Department of Neurology.

Power3 will use its existing proprietary and patent-pending technologies to analyze the samples, seeking new protein biomarkers for the early detection of neurodegenerative diseases to add to its portfolio. The initial shipments of Parkinson’s disease and control subject samples were received in May and October 2007 and to date, 92 Parkinson’s disease patient samples, as well as age and gender matched control samples, have been received and analyzed and have shown greater than expected sensitivity and specificity. The blood serum samples collected from patients in Greece utilized Power3’s rigid sample collection protocols and were shipped to the Company’s CLIA certified laboratory in Houston, Texas, where the analysis was performed. The consistency in the sample results from both the US and Greece, points to how robust this test is in diverse populations. The better than expected Parkinson's test results and the numerous validation studies that are underway for Alzheimer's disease, ALS, and similar neurological disorders, confirm Power3’s commitment to bringing these tests to market in 2008.

Linear discriminant analysis was used to analyze biomarker protein quantities. Discriminant analysis identifies sets of linearly independent functions that will successfully classify individuals into a well-defined collection of groups (i.e. disease groups). The statistical model assumes a multivariate normal distribution for the set of biomarkers identified from each disease group. The outcome of the discriminant analysis is a collection of linear functions that maximize the ability to separate individuals into diseased and non-diseased groups.

In general, if there are m biomarkers, there will be a maximum of (m– 1, g– 1) discriminant functions, where g is the number of disease groups. The discriminant functions themselves are linearly independent. Thus, m– 1 discriminant functions provide incremental and non-redundant discriminant ability.

Also used within discriminant analysis was stepwise discriminant analysis, which evaluates the performance of a discriminant criterion by estimating error rates (probabilities of misclassification) in the classification of future observations. These error-rate estimates include error-count estimates and posterior probability error-rate estimates.

Given a classification variable and several quantitative variables, a stepwise discriminant analysis is performed to select a subset of the quantitative variables for use in discriminating among the classes. The set of variables that make up each class is assumed to be multivariate normal with a common covariance matrix.

Marwan N. Sabbagh / Cleo Roberts Center of Clinical Research at the Sun Health Research Institute

On October 12, 2007, Power3 appointed Dr. Marwan N. Sabbagh to the Company's Scientific Advisory Board. Dr. Sabbagh, a national leader in neurodegenerative disease, is collaborating with Power3 in a 300 patient validation study of blood serum samples using Power3's NuroPro^® diagnostic screening test.

Dr. Sabbagh is currently the Director of Clinical Research at the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute located in Sun City, Arizona. Power3 has a Clinical Trial Agreement with Sun Health. Dr. Sabbagh has been published in seventy reviews, and has written original research articles on Alzheimer's disease and dementia. Additionally, he has published a book on Alzheimer's prevention. Dr. Sabbagh received his medical degree from the University of Arizona in Tucson, completed his residency in Neurology at Baylor College of Medicine in Houston, and completed his fellowship at the University of California, San Diego School of Medicine. He also serves as a staff physician at Sun Health Boswell Hospital where he practices general neurology and specializes in the diagnosis and treatment of Alzheimer's disease. Dr. Sabbagh is a Clinical Instructor in Neurology and provides both clinical and didactic expertise for the geriatric fellowship program.

In February 2008, the Company commenced the 300 patient clinical validation study of its NuroPro^® diagnostic test for Alzheimer’s disease and Parkinson’s disease. Power3 has received 92 samples from the clinical validation study to date and the Company anticipates completion of this clinical validation study in August, 2008. Completed, analyses of 37 Alzheimer’s and healthy control samples from Sun Health Institute are showing very promising results.

The completed clinical validation study with Sun Health and Dr. Sabbagh will include one hundred Alzheimer’s disease patients, one hundred Parkinson’s disease patients and one hundred control subjects.

The Parkinson’s disease patients from Dr. Marwan Sabbagh that are included in the clinical validation study will augment the Parkinson’s disease validation study presently ongoing with the Research Institute of Thessaly in Greece led by Dr. Katerina Markopoulou, the Principal Investigator.

Publications

Power3 has published the discovery of protein biomarkers for esophageal malignancies in the International Journal of Cancer. The article, titled “Alterations in Barrett’s-related adenocarcinomas: A proteomic approach,” was co-authored by Dr. Essam A. Sheta, Director of Biochemistry, and Dr. Ira L. Goldknopf, Director of Proteomics at Power3. Dr. Sheta and Dr. Goldknopf worked in collaboration with Dr. Wael El-Rifai, MD, PhD, Professor of Surgery, Medicine and Cancer Biology and Director of Surgical Oncology Research at Vanderbilt University Medical Center, Nashville, TN.

Esophageal malignancies are the sixth leading cause of cancer death in the world and represent about 1% of the cancers diagnosed in the United States. Dr. El Rifai stated that through the use of Power3’s leading edge proteomic discovery platform, twenty-three biomarkers were identified that have not been described before in this lethal malignancy. Dr. El-Rifai confirmed the differential expression of six of these novel protein biomarkers in a large panel of primary tumors using Western blot, immunohistochemical, and quantitative real time PCR techniques.”

Power3 discovered differential expression of these protein biomarkers in esophageal biopsies of normal, pre-cancerous, and cancerous areas from the same patients, using the company’s quantitative 2D gel electrophoresis platform. Power3’s findings identify a previously unknown potential oncogenic signaling mechanism in Barrett’s tumors, representing a new area that can be developed. This finding is further validation of Power3’s proteomic process as the company continues to build its reputation as leaders in novel proteomic platforms, while moving ahead in commercialization of the company’s blood based early detection proteomic tests for breast cancer, Parkinson’s disease, and Alzheimer’s disease.

Power3’s director of proteomics, Dr. Ira Goldknopf, has published an invited editorial in the February 2008 issue of Expert Review of Proteomics. The editorial, entitled “Blood Based Proteomics for Personalized Medicine, Examples From Neurodegenerative Disease,” outlines how “proteins in the blood serum can tell us what disease pathways and mechanisms…are active in patients.” In his editorial, Dr. Goldknopf cited research completed at Power3 and published in peer reviewed journals. The results demonstrate, “broad and deep implications which liberate a new paradigm to unlock the power of personalized medicine, to monitor proteins in the blood of live patients for diagnosis, differential diagnosis, patient monitoring, selection of treatment options, and for new drug target discovery.”

Power3 is gratified that the editors of Expert Review of Proteomics invited Dr. Goldknopf to share his insights and describe Power3’s groundbreaking work in the study of Alzheimer’s, Parkinson’s, and Lou Gehrig’s diseases. The Company is proud the biotechnology community has recognized and acknowledged Power3’s efforts and advancements in disease diagnosis through blood-based testing. This recognition of the company is further validation of Power3’s leadership position in advancing the science of proteomics for development of molecular diagnostics and targeted therapeutics for neurodegenerative diseases and breast cancer.

Intellectual Property

The Company filed one Utility patent application in the first quarter of 2008 for 47 of the Company's identified blood serum protein biomarkers, and one Provisional patent application on July 9, 2008, comprising parts of Power3's clinically validated biomarker panel for early detection and differential diagnosis of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Lou Gehrig’s (ALS) diseases.

The blood serum protein biomarkers in these patent applications are identified with sufficiently detailed molecular characterization to specify which protein isoforms or variants are the actual biomarkers. With the biomarker proteins fully characterized, and with Power3’s quality controls in place, consistent and significant differences in the concentration of select groups of these protein biomarkers in the blood of patients and age matched normal and disease controls, reflect meaningful indicators of disease processes, processes that also differ between diseases with similar symptoms.

In these patent filings, utilizing the patent pending technologies specified in previous patent application filings, we have demonstrated significant differences in blood serum concentrations between patients for objective differential diagnosis that also provides a rational basis for disease specific mechanism discrimination between:

Similar neurodegenerative diseases: Alzheimer’s disease vs. Lou Gehrig’s disease (ALS) vs. Parkinson’s disease; Alzheimer’s disease vs. non-Alzheimer’s dementias vs. Parkinson’s disease; multiple forms of Alzheimer’s disease

Sporadic vs. familial neurodegenerative diseases: sporadic vs. familial Lou Gehrig’s disease (ALS)

Early vs. more advanced neurodegenerative diseases

These biomarkers provide the capacity for objective blood tests for early, rapid, sensitive, and specific diagnoses of neurodegenerative diseases, which will be a substantial benefit to physicians and patients who now rely on subtleties in symptoms. By the time such symptoms become clear enough to diagnose, the patient has often suffered substantial irreversible neurological damage. Differences in these highly characterized protein biomarkers also provide the type of information that can be employed in the monitoring of patients for potential drug response, disease severity and progression, as well as for potential new drug targets.

We continue to move forward in our commercialization efforts as well as strengthening our intellectual property portfolio, which currently includes eleven patents pending and numerous other patent applications in the pipeline.

Patent Application Filed in Q1 2008		Application Date		Type of Patent
12/069,807: Forty Seven (47) Protein Biomarkers for Neurodegenerative Diseases		2/13/08		US Utility

Patent Application Filed in July 2008		Application Date		Type of Patent
Application No. Pending: Diagnosis of Multiple Forms of Alzheimer’s Disease Based on Differences in Concentration of Protein Biomarkers in Blood Serum Of Patients		7/9/08		US Provisional

The number of pending patent applications as of the period ended June 30, 2008, is 11 as follows:

Qty		Type of Patent
1		Breast Cancer
9		Neurodegenerative
1		Drug Resistance

Liquidity and Capital Resources

The Company’s liquidity and capital needs relate primarily to working capital, development and other general corporate requirements. The Company has not received any cash from operations, other than from the sale of blood serum samples previously gathered. The Company has an immediate need for capital to continue its current operations, and in addition, is seeking additional capital from research grants, collaboration agreements, and other strategic alliances.

Net cash used in operating activities amounted to $1,007,315 for the six months ended June 30, 2008, compared to $1,055,353 for the six months ended June 30, 2007. The change in net cash used in operating activities during 2008 was primarily due to changes in the fair value of derivative liabilities, and net income for the six months ended June 30, 2008 compared to a net loss for the six months ended June 30, 2007.

Net cash provided by financing activities was $982,404 for the six months ended June 30, 2008, as compared to $1,662,137 for the six months ended June 30, 2007. The decrease in cash provided by financing activities during the six months ended June 30, 2008 as compared to the six months ended June 30, 2007 is due to a reduction in borrowing activity in 2008.

As of June 30, 2008, the Company’s principal source of liquidity was $97,970 in cash.

Plan of Operation and Cash Requirements

The Company currently does not have operating revenues from product sales or the performance of services and it continues to experience net operating losses. The Company is actively pursuing third party licensing agreements, collaboration agreements, distribution agreements and similar business arrangements in order to establish a revenue base utilizing its capabilities in disease diagnosis based on protein and biomarker identification, and drug resistance in the areas of cancers, neurodegenerative and neuromuscular diseases. The Company has undertaken clinical validation studies to demonstrate the diagnostic capabilities of its technologies. However, there can be no assurances when revenue-generating agreements will result in continuous revenue streams.

Absent a source of revenues, the Company will require funding in order to carry out its business plan until such time as it is able to generate sustained revenues. The Company’s current cash requirements are approximately $180,000 per month and the Company anticipates that it will require approximately $2,150,000 for the twelve months ended December 31, 2008, to continue its development activities, undertake and perform clinical validation studies, continue its marketing efforts and maintain its administrative infrastructure, as follows:

Estimated Expenditures Required

During Next Twelve Months

General and administrative	$	1,800,000
Patent filings and intellectual property		100,000
Capital expenditures and research agreements		250,000
Total	$	2,150,000

The foregoing is based upon the Company’s current estimated cash requirements. The Company has no significant capital expenditure requirements and does not plan to increase its monthly expenditure rate absent an increase in revenues or additional funding.

The Company will continue to require additional debt or equity financing for its operations, which may not be readily available. The Company’s ability to continue as a going concern is subject to its ability to generate a profit or obtain necessary funding from outside sources.

Off-Balance Sheet Arrangements

At June 30, 2008, the only off balance sheet agreements in place for the Company were a lease in effect for its office space, leases in effect for phone equipment, leases in effect for lab equipment and employment agreements entered with two principal officers.

Accounting for Derivative Instruments

Statement of Financial Accounting Standards (SFAS) No. 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended, requires all derivatives to be recorded on the balance sheet at fair value. These derivatives, including embedded derivatives in Power3's structured borrowings, are separately valued and accounted for on Power3's balance sheet. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.

Lattice Valuation Model

Power3 valued the conversion features in their convertible notes using a lattice valuation model, with the assistance of a valuation consultant. The lattice model values the embedded derivatives based on a probability weighted discounted cash flow model. This model is based on future projections of the five primary alternatives possible for settlement of the features included within the embedded derivative, including: (1) payments are made in cash, (2) payments are made in stock, (3) the holder exercises its right to convert the debentures, (4) Power3 exercises its right to convert the debentures and (5) Power3 defaults on the debentures. Power3 uses the model to analyze (a) the underlying economic factors that influence which of these events will occur, (b) when they are likely to occur, and (c) the common stock price and specific terms of the debentures such as interest rate and conversion price that will be in effect when they occur. Based on the analysis of these factors, Power3 uses the model to develop a set of potential scenarios. Probabilities of each scenario occurring during the remaining term of the debentures are determined based on management's projections. These probabilities are used to create a cash flow projection over the term of the debentures and determine the probability that the projected cash flow will be achieved. A discounted weighted average cash flow for each scenario is then calculated and compared to the discounted cash flow of the debentures without the compound embedded derivative in order to determine a value for the compound embedded derivative.

Black−Scholes Valuation Model

Power3 uses the Black−Scholes pricing model to determine the fair values of its warrants. The model uses market sourced inputs such as interest rates, stock prices, and option volatilities, the selection of which requires management's judgment, and which may impact net income or loss. In particular, Power3 uses volatility rates based upon the closing stock price of Power3’s common stock. Power3 uses a risk free interest rate which is the U.S. Treasury bill rate for a security with a maturity that approximates the estimated expected life of the derivative or security.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s Chief Executive Officer and Chief Accounting Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report on Form 10-Q. Based upon such evaluation, the Chief Executive Officer and Chief Accounting Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act. This conclusion is based upon the number and magnitude of the year end and quarterly adjusting entries.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) of the Company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management, under the supervision of the Company’s Chief Executive Officer and Chief Accounting Officer, conducted an evaluation of the effectiveness of internal control over financial reporting. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was not effective as of June 30, 2008. For the six months ended June 30, 2008 deficiencies related to transactions involving equity issuances and derivatives were identified. Following a review of the deficiencies, management determined that we had incorrectly accounted for equity issuances and derivative valuations during such period. As a result, management concluded that our disclosure controls and procedures were not effective. Management concluded that the following three deficiencies were identified in our control process:

We did not have adequate transaction controls over the accounting, review and processing of certain unusual or complex accounting transactions.

We did not have a systematic and documented program of internal controls and procedures over our accounting and financial reporting process to ensure that unusual or complex transactions are recorded, processed, summarized and reported on a timely basis in our financial disclosures.

There is deficiency in segregation of duties due to the small size of the Company.

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this quarterly report on Form 10-Q.

Additional effort is needed to fully remedy our identified deficiencies as discussed below and we are continuing our efforts to improve and strengthen our control processes and procedures. Our management intends to continue to work with our auditors and other outside advisors, as appropriate, to develop and then apply our controls and procedures with the goal of achieving adequate and effective disclosure controls. We believe that with a properly planned, designed and implemented system of internal controls over financial reporting, our disclosure controls and procedures are expected to become effective.

There have been no significant changes in internal controls, or in factors that could significantly affect internal controls, subsequent to the date the Chief Executive Officer and Chief Accounting Officer completed their evaluation.

Changes in Internal Control Over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the six months ended June 30, 2008, that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Cautionary Statement Regarding Forward-Looking Statements

This Report contains certain forward-looking statements of the intentions, hopes, beliefs, expectations, strategies, and predictions of the Company or its management with respect to future activities or other future events or conditions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are usually identified by the use of words such as “believes,” “will,” “anticipates,” “estimates,” “expects,” “projects,” “plans,” “intends,” “should,” “could,” or similar expressions. These statements are based on certain assumptions and analyses made by the Company’s management in light of its experience and its perception of historical trends, current conditions, expected future developments and other factors believed appropriate. Readers are cautioned that these forward-looking statements are only predictions and that the Company’s business is subject to significant risks and uncertainties, including, without limitation:

The Company’s history of operating losses;

The Company’s need and ability to raise significant capital and obtain adequate financing for its development efforts;

The Company’s ability to successfully develop and complete validation studies for its products;

The Company’s dependence upon and the uncertainties associated with obtaining and enforcing patents and intellectual property rights important to its business;

The uncertainties associated with the lengthy regulatory approval process, including uncertainties associated with the United States Food and Drug Administration (“FDA”) decisions and timing of product development or approval;

Development by competitors of new or competitive products or services;

The Company’s ability to retain management, implement its business strategy, assimilate and integrate any acquisitions;

The Company’s lack of operating experience and present commercial production capabilities; and

The increasing emphasis on controlling healthcare costs and potential legislation or regulation of healthcare pricing.

Although the Company believes that the assumptions underlying the forward-looking statements contained in this report are reasonable, any of the assumptions could be inaccurate, and, therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included in this report, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Except for its ongoing obligation to disclose material information as required by the federal securities laws, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events. Accordingly, the reader should not rely on forward-looking statements, because they are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contemplated by the forward-looking statements.

PART II

Item 1. Legal Proceedings

On October 28, 2005, Power3 received notice of a Petition to Enforce Foreign Judgment citation filed against the Company by KForce regarding an employment fee adjudicated in December 2003 in the state of Florida against the Company, in the amount of $15,873, together with $4,735 in interest. Power3 does not agree with the Foreign Judgment and is attempting to resolve the issue prior to enforcement. No resolution has been achieved on this issue at this time; however, the Company is endeavoring to resolve the petition. This debt is not recorded in accounts payable by the Company because it is the Company’s position that the judgment should never have been entered against Power3, but rather against a different corporate entity, not related to Power3 in any way. The Company’s attorney in this matter feels that no loss is probable, nor will the Company be obligated to pay any sums whatsoever on this matter. The Company has pled improper party and expects to be vacated from the suit since it does not apply to the Company. Power3 has counterclaimed KForce for frivolous claims.

In October of 2006, Trinity Financing filed a lawsuit against the Company claiming default on a promissory note dated December 9, 2005. As security for the Note, Steven Rash and Ira Goldknopf pledged their personal restricted shares of the Company’s stock. As a result of the alleged default in payment of the Note, Trinity Financing seeks to have the restrictive legend removed so the shares may be sold by Trinity Financing in satisfaction of the loan. The Company denied the material allegations and asserted three counterclaims against Trinity Financing. The company asserted that the Note, as well as a prior promissory note executed in favor of Trinity Financing, are usurious. The matter was settled February 4, 2008 with the removal of the restrictive legend.

On August 13, 2007, Gryphon Master Fund LP and GSFF Master Fund, LP filed a lawsuit against the Company claiming a breach of a Securities Purchase Agreement, Convertible Debentures, and Registration Rights Agreement. The plaintiffs claimed the Company failed to timely obtain an effective registration statement for the shares issued to the plaintiffs and refused to recognize anti-dilution rights of the plaintiffs. The Company denies the material allegations of the complaint and asserts numerous affirmative defenses. Power3 has entered into settlement negotiations as of April 20, 2008. On August 13, 2008 the claim above, note, warrants, and all applicable penalties were settled in exchange for 5,240,000 shares of common stock valued at approximately $420,000 based upon the closing price of our common stock at the settlement date.

In October of 2007, Winstead filed suit against the Company for approximately $17,000 in attorney fees. In March 2008, a settlement was reached. The fees have been reduced to $9,000 and a payout schedule has been agreed upon.

Item 1A. Risk Factors

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the six months ended June 30, 2008, the Company issued 7,492,875 unregistered shares of common stock for cash proceeds of $647,404. Proceeds were used to fund operations.

Item 3. Defaults Upon Senior Securities

The Company is in default under the provisions of its October 2004 Securities Purchase Agreement, and accompanying registration rights agreement and debentures. The default stems from the Company’s inability to obtain effectiveness of the registration statement on Form SB-2, as amended (File No. 333-122227) filed pursuant to the registration rights agreement. The registration statement was withdrawn on June 20, 2007. As of the six months ended June 30, 2008, the Company has settled with a number of its Convertible Debenture Holders as previously mentioned above.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to the security holders for a vote during the six months ended June 30, 2008.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit No.		INDEX
31.1*		Certification of Power3 Medical Products, Inc. Chief Executive Officer, Steven B. Rash, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Power3 Medical Products, Inc. Chief Accounting Officer, Marion J. McCormick, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Power3 Medical Products, Inc. Chief Executive Officer, Steven B. Rash, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Power3 Medical Products, Inc. Chief Accounting Officer, Marion J. McCormick, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Steven B. Rash	Chairman and Chief Executive Officer	August 14, 2008
Steven B. Rash

/s/ Marion J. McCormick	Chief Accounting Officer	August 14, 2008
Marion J. McCormick

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Avg

Power 3 Medical Products (PWRM) Inactive 10-Q2008 Q2 Quarterly report

Content analysis